English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The pace of development of new, clinically relevant information in this area can induce difficulties for clinicians in oncology to become fully aware of and quickly react to these advances. Several recent meetings have reported results that are pertinent to the field of HER2/neu and trastuzumab use in breast cancer. This article summarizes some points on HER2 testing and trastuzumab use that should be of value to treating physicians.

Her2 and Trastuzumab in Breast Cancer